Clinical Trials
15 trialsNCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02133196 2026-05-13
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06630611 2025-01-28
PragmaTIL
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03836352 2022-03-31
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Active not recruiting
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT00157209 2015-11-18
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00601796 2013-05-24
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00003269 2011-01-10
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health
Phase 2 Completed
NCT00089726 2007-12-24
A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Cell Genesys
Phase 2 Completed